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Introduction
Malignant mesothelioma (MM) is an uncommon cancer,
caused principally by asbestos exposure. No treatments
after first-line platinum-pemetrexed [1] have shown survi-
val benefit [2], thus novel approaches are needed. Asbestos
exposure induces immunosuppression and immune dys-
function in the mesothelium environment, mainly by
hyperactivation of regulatory T lymphocytes and over-
production of cytokines that inhibit cytotoxic T lympho-
cytes and natural killer cells [3]. Cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4, CD152) modulates and
eventually switches off T cell activation. Tremelimumab
(treme) binds to the CTLA-4 antigen, preventing its nega-
tive regulatory signal to cytotoxic T cells. Results from a
single arm phase 2 study of treme in 29 patients with MM
who progressed on a platinum-based regimen showed
promising 1- and 2- year survival rates and a safety profile
consistent with previous treme studies [4]. This study has
been expanded to enroll 29 patients currently treated with
an optimized dosing schedule.
Study design
This is a phase 2, randomized, double-blind, placebo-
controlled study. Patients with unresectable pleural or peri-
toneal MM who progressed following 1or 2 prior treat-
ments, including a first-line platinum-pemetrexed regimen,
will be randomized in a 2:1 ratio to receive either treme or
placebo. Randomization will be stratified by EORTC status
(low- vs high-risk), line of therapy (second vs third), and
anatomical site (pleural vs peritoneal). Enrollment will
include 180 subjects at approximately 150 centers in multi-
ple countries. Recruiting began in May 2013.
Endpoints
Primary: overall survival. Secondary: durable disease-
control rate (DCR); progression-free survival (PFS);
patient-reported outcomes (pain, disease-related symp-
toms, and time to deterioration of disease-related symp-
toms); duration of response and overall response rate
(ORR); treme safety profile, immunogenicity, and pharma-
cokinetics. Exploratory: DCR, PFS, duration of response
and ORR based on immune related response criteria,
health-related quality of life, disease-related symptoms,
pain, and health status in patients with durable clinical
activity. The association of biomarkers with treme and
clinical outcomes will also be explored.
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